Claims

1. A pharmaceutical preparation comprising a synergistic combination of abacavir and alovudine and a pharmaceutical carrier therefor.

2. A preparation according to claim 1 wherein the alovudine is present in an amount of 1-10 mg per unit dose.

3. A preparation according to claim 2 wherein the alovudine is present in an amount of 0.5-7.5 mg per unit dose.

4. A preparation according to claim 3 wherein the alovudine is present in an amount of 0.5-5 mg per unit dose.

5. A preparation according to claim 1, wherein the abacavir is present in an amount of 200-800 mg per unit dose.

6. A preparation according to claim 5, wherein the abacavir is present in an amount of 300-500 mg per unit dose.

7. A preparation according to claim 1, wherein the alovudine and abacavir are present in a weight ratio corresponding to their respective ED_{50}.

8. A preparation according to claim 1, wherein the alovudine and abacavir are present in the ratio 1-10:200-800

9. A patient pack comprising alovudine and/or abacavir and an information insert containing directions on the use of both alovudine and abacavir together in combination.

10. Use of abacavir and alovudine together for the treatment of multiresistant HIV, wherein the use comprises simultaneous, combined or sequential administration of alovudine and abacavir.

11. Use according to claim 10, wherein the use comprises administration of a preparation as defined in any one of claims 1-8 or the patient pack of claim 9.